"Overweight and obesity are established risk factors that contribute to greater severity and more frequent exacerbations of ...

(MENAFN- Market Press Release) December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 billion in 2025 and is projected to grow at a 14% CAGR through 2032.

GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...

Maximum and minimum temperatures are likely to be around 31 degrees Celsius and 17 degrees Celsius, respectively, according ...

Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

In return for $10 million upfront, Foresee sold the global rights for its MMP-12 inhibitor programs to Primevera Therapeutics ...

Flu cases are surging in some states, including New Mexico, Colorado and Texas. Here's what to know about flu in Arizona.

Flu cases are rising across the U.S. Here's what you need to know about symptoms, flu duration and the new strain ...

Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...

Investing.com -- China has approved GSK Plc ’s (LON:GSK) Nucala as an add-on maintenance treatment for adults with chronic ...

Doctors and public health officials across eastern Iowa say flu activity remains elevated this winter — and they’re ...

(n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points ...